EGFR and non-small cell lung carcinoma: Furmonertinib Mesylate Neoadjuvant Treatment of Resectable Stage II-IIIB Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR)Sensitive Mutation: a Prospective, Muliticenter, Open Label, Phase II Single-arm Study